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Abstract 
The quassinoid analogue NBT-272 has been reported to inhibit MYC, thus warranting a 
further effort to better understand its preclinical properties in models of embryonal tumors 
(ET), a family of childhood malignancies sharing relevant biological and genetic features 
such as deregulated expression of MYC oncogenes.  
In our study, NBT-272 displayed a strong anti-proliferative activity in vitro that resulted from 
the combination of diverse biological effects, ranging from G1/S arrest of the cell cycle to 
apoptosis and autophagy. The compound prevented the full activation of both the eukaryotic 
initiation factor 4E (eIF4E) and its binding protein 4EBP-1, regulating cap-dependent protein 
translation. Interestingly, all responses induced by NBT-272 in ET could be attributed to 
interference with two main pro-proliferative signaling pathways, i.e. the AKT and the 
MEK/extracellular signal-regulated kinase (ERK) pathways. These findings also suggested 
that the depleting effect of NBT-272 on MYC protein expression occurred via indirect 
mechanisms, rather than selective inhibition. Finally, the ability of NBT-272 to arrest tumor 
growth in a xenograft model of neuroblastoma plays a role in the strong anti-tumor activity of 
this compound, both in vitro and in vivo, with its potential to target cell-survival pathways 
that are relevant for the development and progression of ET. 
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Introduction 
Embryonal tumors (ET) represent an important group of childhood malignancies arising from 
different tissues of fetal origin (1, 2). Medulloblastoma (MB) is a tumor of the central nervous 
system, originating from granular progenitor cells of the cerebellum (3) and accounting for 
about 20% of all childhood brain tumors (4). Neuroblastoma (NB) is the most common extra-
cranial solid cancer in children originating from the sympathetic nervous system (5, 6). 
Constant progress has been achieved in clinical practice by increasing the overall survival rate 
of MB and NB patients although novel therapeutic strategies are still needed, particularly to 
treat the high-risk patients characterized by a more aggressive disease and poor prognosis. In 
both MB and NB, high grade malignancy is often associated with overexpression or 
amplification of MYC oncogenes (7-11) playing a role in embryogenesis and, if aberrantly 
expressed, in tumor development as well (12). 
There is a long history of therapeutic benefits produced by natural compounds and some of 
these have formed the backbone for further targeted chemical modifications improving 
efficacy and selectivity. Quassinoids have been investigated for their anti-neoplastic 
properties (13), which has led to the identification of interesting candidates such as 
bruceantin, with significant inhibitory effects on leukemia, lymphoma, and myeloma cell 
growth, both in vitro and in vivo (14). Bruceantin was reported to induce apoptosis and cell 
differentiation, thus justifying efforts to develop quassinoid analogues with improved 
efficacy.  
Among the derivatives of bruceantin, NBT-272 displayed a significantly stronger toxicity 
compared to the parent molecule, as tested in different models of hematological and solid 
tumors (15, 16). Moreover, NBT-272 was reported to induce downregulation of c-MYC in 
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MB-derived cells (16), thus raising the question of the mechanisms underlying NBT-272’s 
cytotoxicity and its selectivity for MYC in ET. 
Besides activating programmed cell death, quassinoids were shown to arrest cell growth by 
impairing protein synthesis mediated by the eukaryotic translation initiation factor 4E (eIF4E) 
(17). The phosphorylation status of eIF4E plays an important biological role in modulation of 
normal cell growth in response to extracellular stimuli and during development (18). 
However, eIF4E was also reported to be an oncogene (19) and its transformation properties 
were attributed, at least in part, to induction of cell cycle progression through cyclin D1 and 
MYC (20). Activation of eIF4E itself is mainly regulated by two pathways, namely the 
mitogen-activated protein kinase (MAPK) pathway (21) and the AKT/mammalian target of 
rapamycin (mTOR) pathway via the 4E binding protein (4EBP-1) (22). 
In the present study, we have investigated the effect of NBT-272 in different cellular 
models of ET, both in vitro and in vivo. The compound triggered multiple cellular responses, 
ranging from cell cycle arrest to induction of autophagy, which are downstream effector 
mechanisms of the AKT/mTOR and ERK pathways. In turn, interference with these signaling 
events could also explain the inhibitory effect of NBT-272 on protein synthesis and on 
expression of c-MYC/MYCN in different ET entities. 
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Materials and Methods 
Cell lines 
The following human cell lines were used: the neuroblastoma SK-N-BE, SH-SY5Y, and 
WAC-2 (23) (G. M. Brodeur, Children's Hospital, Philadelphia, MA), retinoblastoma Y79 
and WERI (A. Eggert, University Children's Hospital, Essen, Germany), Ewing’s sarcoma 
family of tumors (ESFT) A673 and TC71 (H. Kovar, St. Anna Children’s Cancer Research 
Institute, Vienna, Austria), malignant rhabdoid tumor (MRT) LP and MON (O. Delattre, 
Institut Curie, Paris, France). Medulloblastoma DAOY and D341 were purchased from 
American Type Culture Collection (ATCC). Cells that were not purchased from ATCC were 
authenticated by comparative genomic hybridization (in the laboratories mentioned above or 
as described below). The clone DAOY M2 (overexpressing c-MYC) was kindly provided by 
D. Stearns (Johns Hopkins University, Baltimore, MD) (11). NB, ESFT, and MRT cell lines 
were grown in RPMI medium (Life Technologies/Invitrogen, Carlsbad, CA) supplemented 
with 10% (v/v) fetal calf serum (FCS) and penicillin/streptomycin (PS)/L-glutamine, whereas 
RB cells were grown in DMEM (Invitrogen, Carlsbad, CA) supplemented with 15% (v/v) 
FCS Gold (Invitrogen ), 10 μg/ml insulin (Sigma-Aldrich, St. Louis, MO), 50 μM 2-β-
mercaptoethanol (Sigma-Aldrich), and PS/L-glutamine. MB cells were cultured in Richter's 
zinc option medium (Invitrogen) supplemented with 10% (v/v) FCS and PS/L-glutamine. 
 
Array CGH 
The ET-derived cell lines used in the study were profiled by array comparative genomic 
hybridization (aCGH) using a custom 60K Embryonal Tumor array CGH-chip (ET-aCGH 
chip) (Agilent Technologies, Santa Clara CA), as described by Kumps et al. (BMC Genomics, 
in press). 
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Cell viability, clonogenic, and apoptosis assays 
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS)-based CellTiter 96® AQueous One assay (Promega, Madison, WI) was 
used to quantify cell viability. Colony formation in agar was tested by seeding single cells 
(4,000 per well) in agar-containing medium (0.35% (w/v) final concentration) on top of a 
0.5% (w/v) agar-layer. Apoptosis was investigated by quantifying the activation of caspases, 
by using the Caspase-Glo 3/7 Assay (Promega) according to the manufacturer’s instructions. 
The In Situ Cell Death Detection Kit (Roche, Mannheim, Germany) was also employed to 
evaluate the pro-apoptotic response of ET cells. The TUNEL reaction was performed in the 
presence of fluorescein-labeled nucleotides and followed by detection under a fluorescent 
microscope (Axioskop 2, Zeiss).  
 
Cell cycle analysis 
Cells (5-10x105) were treated for the indicated time-intervals with different doses of NBT-
272 or mock-treated (control). After washing with PBS, cells were washed and harvested in a 
2 mM EDTA/PBS solution. Cell pellets were fixed with ice-cold 70% ethanol on ice for 40-
60 min and, after centrifugation at 2500 g for 5 min, resuspended with 50 μg/ml propidium 
iodide (PI)/PBS containing 100 U/ml RNAase (Sigma-Aldrich). The DNA content was 
estimated by using a BD FACS Canto II flow cytometry system for acquisition and the Flojo 
software for the data analysis. 
 
Gene expression analysis by PCR arrays 
Total RNA from DAOY, D341, SK-N-BE, and SH-SY-5Y cells, treated with 20 nM NBT-
272 for 24 h or left untreated, was subjected to reverse transcriptase (RT) (RT² First Strand 
Kit, SABiosciences, Frederick, MD). The resulting cDNA was used as a template for RT² 
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Profiler™ PCR Array (SABiosciences) for pathway-focused gene expression analysis (using 
sets of arrayed TaqMan probes for cell cycle and apoptosis genes). Gene expression was 
expressed as log2Ratio (Ratio=2^-ΔΔCt), relative to normalization to untreated control 
samples and to the average expression of 5 house-keeping genes (B2M, HPRT1, RPL13A, 
GAPDH, and ACTB). Only statistically significant gene expression changes over three 
independent experiments were considered. 
 
Western blot analysis 
Total cell lysates were prepared in RIPA buffer (50 mM Tris-HCl, pH 7.5, 0.1% sodium 
laurilsulfate, 0.1% sodium deoxycholate, 150 mM NaCl, 1% NP40, 1 mM EDTA, and 1 mM 
EGTA), supplemented with protease inhibitors (Roche) and phosphatase inhibitors (10 mM 
sodium fluoride, 10 mM sodium orthovanadate, and 10 mM sodium -glycerophosphate. The 
amount of protein was determined by BCA Protein Assay (Pierce, Rockford, IL). Cell lysates 
in SDS-sample buffer were boiled for 8 min and equal protein amounts were resolved by 4-
12% gradient SDS-PAGE and immunoblotting using PVDF membranes. The antibodies 
reacting against the following proteins were employed: cyclin D1, caspase-3, AKT, mTOR, 
phospho-ERK 1/2(Tyr202/204) (Santa Cruz Biotechnology, Santa Cruz, CA); ERK, phospho-
AKT(Ser473), phospho-MEK1/2(Ser217/221), phospho-RB(Ser795), RB, phospho-S6 
(Ser235/236), S6, phospho-mTOR(Ser2248), phospho-MNK1(Thr197/202), MNK1, 
phospho-eIF4E(Ser209), eIF4E, 4EBP-1, phospho-4EBP-1(Thr37/46), cyclin E, CDK2, 
CDK4, PARP, LC-3, c-MYC, MYCN, and ATG5 (Cell Signaling, Danvers, MA); β-tubulin 
and β-actin antibodies were from Sigma-Aldrich, whereas the anti-SQSTM1/p62 was 
purchased from BIOMOL International. In order to inhibit proteasome-dependent protein 
degradation, cells were treated with 50 μM MG-132 (Sigma-Aldrich). The PI3K/mTOR 
inhibitor BEZ-235 was purchased by Axon Medchem.  
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Transmission Electron Microscopy 
After treatment (with NBT-272, rapamycin, or vehicle) for different time-intervals, DAOY 
and SK-N-BE cells were subjected to fixation at room temperature for 30 min with 2% 
glutaraldehyde and 0.8% formaldehyde in 50 mM sodium cacodylate (pH 7.3), followed by 
30 min exposure to 1% OsO4 and 1.5% K4Fe(CN)6 in 50 mM sodium cacodylate (pH 7.3). 
Fixed samples were contrasted using 2% uranyl acetate in water for 2 h, progressively 
dehydrated in increasing concentrations of ethanol, and embedded into epon (Catalys, 
Duebendorf, Switzerland). Ultrathin sections of 50 nm were prepared and contrasted with 
uranyl acetate and lead citrate. Samples were analyzed by using a CM 100 transmission 
electron microscope (Philips, Leiden, Netherlands). 
 
In vivo xenograft model 
Human NB SH-SY5Y cells were stably transfected with a pLentiV5-Luciferase-expressing 
vector (Invitrogen) as described elsewhere (24). SH-SY5Y-LUC clones were grown under 
standard conditions in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% (v/v) 
FCS, L-glutamine, and blasticidine for selection. 
Eight-weeks-old female athymic nude mice from Harlan Laboratories (Udine, Italy) were 
inoculated subcutaneously in the right rear flank with 2x106 SHSY5Y-LUC cells, injected in 
100 μl PBS solution. Tumor cell growth was monitored weekly by measuring luminescence 
emission, referred to as bioluminescence imaging (BLI) levels, using the IVIS 3D Illumina 
Imaging System (Xenogen Corp. Alameda, CA). A detailed procedure is available by Caliper. 
The BLI/tumor size ratio was quantified by encircling the luciferase-emitting areas using the 
Living Images Software 3.2 (Xenogen, Alameda, CA). Three weeks after implantation, the 
mice were divided into two homogeneous groups based on their BLI level (photon/sec/cm²). 
on March 14, 2014. © 2010 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 1, 2010; DOI: 10.1158/1535-7163.MCT-10-0539 
10 
 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2010  American Association for Cancer Research 
 
 
Each group received either 10 μM/week of NBT-272 or vehicle (EtOH 0.003%/PBS), 
administered as 100 μl solution each time, three times a week. The analysis of the tumor 
growth was performed 3, 4, and 6 weeks after the first NBT-272 administration. The dose was 
adjusted by taking into account preliminary data provided by NaPro Bio Therapeutics, Inc. 
(MTD=0.9 mg/Kg/week) (15) and the in vitro results. The treatment was performed for 6 
weeks before the animals were sacrificed and tumor samples were analysed by 
immunohistochemistry and western blotting. Quantitative data analysis of the tumor size was 
performed by ANOVA statistical tests, using the Statview program. 
All animal experiments were conducted according to national and international guidelines 
and following approval by the Institutional Animal Care and Ethical Committee of CEINGE-
University of Naples Federico II (Protocol #29 - 30/09/2009) and of the Italian Ministry of 
Health (Dipartimento Sanità Pubblica Veterinaria D.L. 116/92). 
 
Immunohistochemistry  
Paraffin embedded tumor samples were treated with xylene, heated for 45 min (in citrate 
buffer, pH 6.0), and finally treated 15 min with 1% H2O2 (Carlo Erba Reagents, Rodano, 
Italy). Tissues for immunohistochemistry (IHC) were blocked with 3% BSA-5% total goat 
serum-0.3% Tween 20/PBS (1 h, room temperature). Primary antibodies reactive against 
human Ki67 (M7240, Dako) and human cleaved caspase-3 (9661, Cell Signaling) were used 
(1 h, room temperature, diluted 1:100 in blocking solution). After incubation with a biotin-
conjugated secondary antibody (1 h, room temperature), the detection was performed in the 
presence of 3,3'-diaminobenzidin (Dako, Glostrup, Denmark) according to the manufacturers’ 
protocol. The sections were counterstained by hematoxylin/eosin (H&E) (Bio Optica, Milano, 
Italy), washing three times with 0.2% Triton X-100/PBS after every incubation steps. As 
negative control, blocking solution was used instead of the primary antibody. 
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Results 
NBT-272 strongly impaired cell growth in ET-derived cell lines. NBT-272 (NaPro Bio 
Therapeutics, Inc.) (Fig. 1A) is a semi-synthetic analogue of bruceantin (14, 17), with 10-fold 
higher toxicity than the parent compound in vitro (15). Previously published data showed the 
ability of NBT-272 to drastically reduce the protein expression level of the oncogene c-MYC 
in MB-derived cell lines (16), although the exact mechanism of action remained unexplored. 
In the present study, the biological responses induced by NBT-272 were investigated in a 
panel of 13 cell lines, representative of six different ET entities (Fig. 1). Expression of c-
MYC and MYCN was evaluated in each cell line both at protein (Fig. 1SA) and mRNA levels 
(Fig. 1SB); these varied significantly, reflecting the gene expression ranging from single copy 
to gene amplification. 
The ET cell lines were profiled for copy number changes (gain/loss) using aCGH. In Fig. 
2S, the aCGH data of 8 cell lines are reported. Some cell lines displayed very few genomic 
aberrations (1q gain in the MRT cells LP, and 1q gain and 8 gain in MB D341), whereas 
others have very complex profiles, such as WERI cells with a 1q-gain region that appeared 
very discontinuous. 
The effect of NBT-272 was first evaluated in terms of cell viability, clearly showing a very 
potent effect of the compound in all selected ET-derived cell lines (Fig. 1B, C). The IC50 
values, calculated from the dose-response curves, varied in the nM range of concentration, i.e. 
about two orders of magnitude lower compared to many small-molecule inhibitors 
investigated as anti-cancer drugs. Additionally, five representative ET cell lines (WAC-2, SK-
N-BE, A673, MON, Wit-49) were tested for anchorage-independent growth in soft agar in the 
presence of NBT-272 (Fig. 1D). The compound reduced colony formation by 50% (compared 
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with mock-treated controls) at doses that were similar or lower than the IC50 obtained in cell 
viability assays (Fig. 1C). 
 
NBT-272 induced cell cycle arrest at the G1/S transition. In order to identify which 
molecular characteristics were responsible for NBT-272’s toxicity, we sought to investigate 
the diverse biological responses triggered in ET cell lines by the compound. The effect on 
cellular distribution at different stages of the cell cycle was evaluated by DNA staining in MB 
and NB cells. In dose-response experiments at different time points, 5 nM NBT-272 was 
already sufficient to almost halve the population of replicating DAOY cells after 24 h, with a 
concomitant increase in G1 population (Fig. 3S). This observation was found to extend to NB 
cell lines (WAC-2, SK-N-BE, and SH-SY5Y) (Fig. 2A). Here, NBT-272 induced a similar 
effect after 16 h treatment, thus suggesting that blocking the cell cycle progression at the G1 
to S transition occurs as one of the earliest mechanisms leading to proliferative arrest. 
Consistent with the data obtained by cytofluorimetry, NBT-272 induced loss of cyclin D1 
(CCND1) and of its interacting partner the cyclin dependent kinase (CDK)4 (Fig. 2B). These 
proteins are both important regulators of the cell cycle progression through the G1 phase (25), 
along with the phosphorylation status of RB, which changes throughout the cell cycle with 
highest levels when cells enter the S phase (26). Consistent with an arrest in the G1/S 
transition, RB was hypophosphorylated on treatment with NBT-272 (Fig. 2B). On the 
contrary, the effect on CCNE1/CDK2 was transient. 
Two NB cell lines (SH-SY5Y and SK-N-BE) and the MB cells DAOY and D341 were 
treated for 24 h with 20 nM NBT-272, followed by expression profiling of 84 cell cycle-
related genes by qRT-PCR. Fig. 4SA illustrates the statistically significant gene expression 
changes induced by NBT-272. The 23 transcripts fell into three functional categories: i) G1/S 
transition of the cell cycle; ii) DNA damage (e.g. growth arrest and DNA damage-inducible 
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alpha protein, GADD45A); and iii) regulation of transcription elongation. The most relevant 
changes concerned genes involved in the G1 arrest, in support of the data from our biological 
assays (Fig. 2). For instance, consistent with a G1/S block of the cell cycle, the mRNA level 
of CDK2 decreased, while the inhibitor molecules CDKN1A/p21Cip1and CDKN1B/p27Kip 
were induced on treatment (Fig. 4SA). Whereas CCND1 and CCNE1 were regulated solely at 
the protein level (Fig. 2B), other cyclins and CDK molecules involved in the RNA 
polymerase II-mediated gene transcription (CCNC/CDK8, CCNH/CDK7, and CCNT/CDK9) 
were found to be upregulated. 
 
Apoptosis was induced by NBT-272 in a cell type-dependent manner. Induction of 
apoptosis was assessed by quantifying activation of caspases-3/7 induced by NBT-272 (Fig. 
3A). The pro-apoptotic response to NBT-272 varied significantly in a cell type- and tumor-
dependent way. This observation was also confirmed by Cell Death ELISA assays (Roche) 
(not shown). Whereas NBT-272 concentrations as small as 10 nM triggered apoptosis in MB-, 
ESFT-, and MRT-derived cell lines after 24 h, the same doses had a very modest pro-
apoptotic effect in other cellular models, particularly in NB (Fig. 3A). The limited pro-
apoptotic effect of NBT-272 in MB and NB cells was also shown by immunoblotting (Fig. 
3B), where caspase-3 could be only detected as full length protein and PARP cleavage was 
only induced in MB cell lines (e.g. in D341, Fig. 3B). This observation was confirmed by 
TUNEL assay, where NBT-272 was able to induce a breakage of the genomic DNA in DAOY 
cells (Fig. 5S). 
Using a similar approach to that employed for cell cycle-related genes, we investigated the 
transcriptional changes related to apoptosis triggered by NBT-272 (Fig. 4SB). Among the 
differentially expressed genes, we found key components of both the extrinsic and the 
intrinsic pathways of apoptosis, mainly upregulated on treatment with the compound. This 
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was the case with pro-apoptotic members of the Bcl-2 family (BIK, BAD, and BAK) and with 
proteins bearing the caspase recruitment domain (CARD), such as Bcl-10, PYCARD and 
RIPK2, implicated in the recruitment and binding of caspases. Another major group, namely 
genes encoding for ligands and receptors of the tumor necrosis factor (TNF) superfamily, was 
induced (Fig. 4SB). It included TNF-α, TNF-β/LTA, TNFSF10/TRAIL and their 
corresponding receptors TNFRSF10A and TNFRSF10B. Also the expression of TNFRSF5, 
TNFRSF9, and TNFRSF6/FAS increased on NBT-272 treatment, altogether indicating 
enhanced cell responsiveness to death receptors-mediated signaling. 
 
NBT-272 triggered autophagosome formation. Because NBT-272 induced apoptosis 
with differing efficiency in the ET cell lines tested, we sought additional mechanisms that 
could lead to cell death. Formation of the distinctive traits of autophagy was investigated at 
the ultrastructure-cellular level by transmission electron microscopy (TEM), thus revealing 
induction of a high number of double-membrane structures containing cellular material (i.e. 
cytosolic cargo molecules and organelles), described as autophagosomes (27).  
In Fig. 3C, TEM images of DAOY (MB) and SK-N-BE (NB) cells are reproduced. 
Compared with mock-treated controls (panels a, b), treated cells (20 nM NBT-272, 16 h) 
displayed all the characteristic signs of autophagy induction, in particular formation of large 
autophagosomes (arrow heads in panels e, f, g) and increased lysosomes and vacuoles. 
Moreover, the cytosol appeared looser than in control cells, the nuclear envelope became 
irregular, the mitochondria acquired swollen crests indicative of dysfunctional activity, and 
myelin figures could be visualized as electron-dense structures. As positive control, DAOY 
cells were treated separately with rapamycin (200 nM, 48 h) (panel h), inducing autophagy as 
an event associated with inhibition of mTOR (28). On comparing the effect of the two 
compounds in DAOY cells, NBT-272 proved to be a much stronger inducer of autophagy. 
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Formation of autophagosomes requires a rather complex rearrangement of Atg proteins, 
including the protein conjugation system generating the complex Atg5-Atg12 (29), which was 
detected by immunoblotting, on treatment of DAOY cells with 20 nM NBT-272 (Fig. 3D). 
Concomitantly, we were able to demonstrate the degradation of sequestosome 1 
(SQSTM1/p62), i.e. a multifunctional adaptor molecule driving the degradation of 
polyubiquitinated proteins such as those tagged for autophagic clearance (30). Further, we 
documented the conversion of the microtubule-associated protein light chain 3 (LC3-I) into its 
membrane-interacting counterpart (LC3-II), which is a well documented marker of autophagy 
induction. 
 
MYC depletion resulted as an indirect effect of NBT-272. Because NBT-272 was 
originally described as a MYC inhibitor, we evaluated the correlation of the expression of c-
MYC and MYCN in the ET cell lines (Fig. 1S) with cell sensitivity to the compound. 
However, only the MB cell line D341 (bearing c-MYC amplification) was significantly more 
sensitive to NBT-272 than DAOY cells expressing c-MYC as single copy gene (Fig. 1) (16), 
whereas cells from other ET entities displayed a similar sensitivity to NBT-272 (Fig. 1). 
Moreover, again regardless of the MYC isoform expressed and the gene copy number of c-
MYC/MYCN, NBT-272 induced depletion of MYC in several ET cell lines, although 
exclusively at the protein level (Fig. 4A). In contrast, mRNA expression was either left almost 
unchanged (e.g. MYCN in SK-N-BE cells) or was enhanced (e.g. c-MYC in D341 cells) by 
NBT-272 in a dose-dependent manner (Fig. 4A). 
The MYC family of transcription factors is known to have short half-lives (31). Therefore, 
we researched whether NBT-272 could have an effect on protein stability, thus helping to 
explain MYC depletion. In fact, by using the proteasome inhibitor MG132 (32) in 
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combination with NBT-272, c-MYC was already almost completely rescued after 4 h (Fig. 
4B). 
Additional lines of evidence supported an indirect effect of NBT-272 on MYC. Two small-
molecule inhibitors specifically targeting the MYC/Max interaction (33, 34) did not show the 
same profile of activity as NBT-272 (Fig. 4C). In fact, significant cell viability could still be 
measured at high doses of both Mycro3 and 10058-F4. In particular, WAC-2 cells were 
almost unaffected by either of the compounds, whereas 103-times less concentrated NBT-272 
completely arrested cellular growth. 
Finally, only a limited number of gene expression changes induced by NBT-272 matched 
with the transcriptional effects of siRNA-mediated silencing of c-MYC in DAOY cells (Fig. 
6S, 4D). In fact, only a restricted number of genes were up-/downregulated in both sets of 
experiments, i.e. 11 apoptosis-related and 11 cell cycle-related transcripts (out of 84 in each 
analysis). Among them, even fewer genes were known direct targets of c-MYC (i.e. 
GADD45A, BIRC3, DFFA, CDK6, CDKN1A/p21, and PCNA). On the other hand, genes 
reported to be MYC targets exhibited a different expression profile, i.e. they were mostly 
downregulated in c-MYC-depleted cells, but induced or left unchanged in cells treated with 
NBT-272 (e.g. the cyclins CCNB1, CCNB2, CCND2, CCNH, and the DNA replication 
regulators MCM4 and MCM5). 
Altogether, these results led us to conclude that a direct inhibition of MYC is unlikely to 
explain the effects triggered by NBT-272 in ET cells, which are more likely to be the result of 
more complex mechanisms and of interference with upstream pathways. 
 
NBT-272 targeted components of the AKT and ERK signaling pathways. In order to 
improve our understanding of the regulatory mechanisms leading to arrest of the cell cycle, 
apoptosis, and autophagy, we analyzed the activation status of two signaling pathways, i.e. the 
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AKT/mTOR and the MEK/ERK pathways, regulating these cellular responses (35). 
Furthermore, both pathways have been documented to be relevant also in the development of 
ET.  
Fig. 5A shows the effect of NBT-272 on the activation status of AKT varying in different 
cell lines, with phosphorylation at Ser473 significantly decreasing in WAC-2, SK-N-BE, and 
SH-SY5Y cell lines, but slightly enhanced in DAOY cells. On the other hand, the level of 
phosphorylated ERK 1/2 (p44/p42) diminished in all cell lines tested, although with different 
kinetics (Fig. 5A), suggesting a different sensitivity of the two pathways to NBT-272. In order 
to test whether NBT-272 had a direct effect on the enzymatic activity of either AKT or ERK 
and could thus be regarded as a kinase inhibitor, we quantified the in vitro kinase activity of 
271 purified recombinant kinases (Fig. 7SA). However, none of them were significantly 
impaired by NBT-272 (20 nM). Additionally, different subunits and isoforms of 
phosphoinositide-3 kinase (PI3K) were tested (Fig. 7SB), again showing no effect from NBT-
272 (20 nM).  
Although the exact mechanism of action of NBT-272 remained unsolved, the compound 
clearly affected AKT- and ERK-dependent cellular functions. The downstream target of ERK, 
MNK1 (36), was also deactivated upon treatment with NBT-272, whereas the upstream 
kinase MEK1/2 was only slightly affected (Fig. 5A). MNK1 is known to phosphorylate both 
eIF4E and its repressor, 4EBP-1 (37). 4EBP-1 is also a direct target of mTOR, playing a key 
role as regulator of protein translation downstream of AKT (22). Interestingly, regardless of 
the AKT activation status, phosphorylation of both eIF4E and 4EBP-1 was impaired by NBT-
272 in MB and NB cells (Fig. 5B), thus preventing the cap-dependent protein translation 
machinery from being completely functional. Additionally, the phosphorylation status of the 
ribosomal S6 protein, target of mTOR via S6 kinase (S6K) (38), was proven to be unaffected, 
thus reinforcing the idea of a 4EBP-1-dependent block of protein synthesis. 
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Moreover, we asked whether the cellular sensitivity to NBT-272-mediated G1/S block of 
the cell cycle, apoptosis, or autophagy would vary if one of the pathways had been affected by 
using specific inhibitors. To test the relevance of the mTOR/AKT pathway, BEZ235 was used 
(39). A pre-treatment with the PI3K/mTOR inhibitor increased both depletion of CCND1 and 
degradation of SQSTM1/p62 when compared to NBT-272 alone (Fig. 8SA), whereas no 
significant enhancement of the pro-apoptotic functions of NBT-272 was observed (Fig. 8SB). 
Although BEZ235 alone had apparently no effect, under these conditions, on the expression 
of the cell cycle and autophagy markers in DAOY cells, the inhibitor was functional, as 
demonstrated by the strong deactivation of AKT (Fig. 8SA) and the induction of apoptosis 
(Figure 8SB). 
 
NBT-272 blocked tumor progression in a xenograft model of NB. NB cells bearing a 
transgene encoding luciferase (SH-SY5Y-LUC) were injected in the flank of ten athymic 
nude mice and were allowed to develop for three weeks. The effect of the i.p. administration 
of NBT-272 (10 μM/week) and of the vehicle (0.003% EtOH/PBS) on the tumor growth was 
monitored by quantifying the luminescent signal from engrafted SH-SY5Y-LUC cells. After 
six weeks of treatment, the tumors almost stopped growing in the mice receiving NBT-272, 
whereas the human NB SH-SY5Y cells expanded into large tumors in the control animals 
(6A, B and 9S). In fact, a 6.3-fold increase of tumor size could be detected in the control 
group compared with the NBT-272-treated (p = 0.037 according to Student’s t-test). The 
result clearly indicated that NBT-272 has a significant anti-proliferative effect on the tumor 
development in vivo. The hemotoxylin/eosin staining of some representative tumor samples 
showed a compact and rounded shape of the tumors, which were characterized by a very 
dense cell distribution with some necrotic areas (Fig. 6C, panel a-d). Tumors from NBT-272-
treated mice showed a clear reduction of Ki67-positive cells (Fig. 6C, panels f, h), whereas a 
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prominent cellular perinuclear staining in vehicle-treated mice was observed (panels e, g), 
thus confirming the significant anti-proliferative effect of NBT-272 also in vivo. Activation of 
caspase-3 was also evaluated (panels i, l) and show that the treatment with NBT-272 did not 
induce a significantly higher induction of apoptosis as compared to control tumors. This result 
confirmed our findings in vitro (Fig. 3A, B) by referring to the same cellular model, i.e. SH-
SY5Y cells, which were used to induce the tumors. Finally, NBT-272 treatment had an effect 
on MYC stability/expression in the tumors, in which ERK activation was also impaired (Fig. 
6D). 
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Discussion 
A fine regulation of protein turnover by a tunable modulation of protein stability requires 
specific post-translation modifications (such as phosphorylation) of key molecules. Many of 
these molecules are significant components of pro-survival pathways and often play a crucial 
role in tumor development and progression, in conditions of constitutive and growth factors-
independent activation. In past decades, great efforts have been made to interfere with those 
signaling pathways by employing different strategies of targeted therapy, ranging from 
antibodies against receptor tyrosine kinases (RTK) to small-molecule inhibitors blocking 
downstream signaling effectors. Downstream of RTK activation, the induction of MYC 
transcription factors and of their pleiotropic effects on cell growth has been frequently 
associated with neoplastic transformation. Therefore, MYC itself clearly represents an 
attractive target for anti-cancer therapy (40), also due of its correlation with poor prognosis 
and high grade malignancy in many types of tumors, including pediatric malignancies (10, 11, 
41, 42). 
In the context of MYC-overexpressing ET tumors, we wanted to investigate the biological 
responses of a group of ET-derived cell lines to NBT-272, a small molecule of about 550 Da, 
previously described as inhibitor of MYC (15, 16). Its toxicity and ability to prevent colony 
formation in vitro indicated a very strong effect of NBT-272 at low concentrations. 
In the search for an association between toxicity of NBT-272 and MYC expression levels 
in different ET cell lines, no significant correlation could be found. This observation led us to 
question any direct effect of NBT-272 on the oncogene, which would more likely be the result 
of different mechanisms, such as interference with protein synthesis and stability, affecting 
also the MYC family members known to have short half-lives (31). Indeed, we could observe 
on March 14, 2014. © 2010 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 1, 2010; DOI: 10.1158/1535-7163.MCT-10-0539 
22 
 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2010  American Association for Cancer Research 
 
 
that inhibition of the proteasome-dependent protein degradation pathway restored the 
depleting effect of NBT-272 and almost completely stabilized c-MYC. Moreover, the effect 
induced by two specific MYC/Max inhibitors (33, 34) and by c-MYC silencing in ET cells did 
not match the cellular response to NBT-272, again detrimental to the hypothesis of a direct 
effect on MYC. This conclusion, however, certainly does not exclude that MYC inhibition 
contributed to the panel of cellular responses observed upon NBT-272 treatment.  
Even though the compound is not a direct kinase inhibitor, our study indicated the ability 
of NBT-272 to interfere with the activation status of different components of the AKT/mTOR 
and MEK/ERK signaling pathways. We therefore attributed the effect of NBT-272 on 
apoptosis, cell cycle, and autophagy to its ability to interfere with these pathways. Indeed, the 
basal level phosphorylation of ERK1/2, MNK1, and AKT in MB and NB cells was impaired 
by NBT-272, under the same conditions that induced efficient cell cycle arrest (G1/S) and 
autophagosome formation. It is also relevant to emphasize that the two pathways converge to 
regulate the activation status of eIF4E and 4E-BP1, both dephosphorylated (i.e. inactive) in 
the presence of NBT-272, thus leading us to speculate that targeting these pathways would 
prevent full activation of the cap-dependent protein translation machinery. Furthermore, MYC 
depletion could possibly be explained, not only as an effect of protein synthesis inhibition, but 
also as a consequence of decreased phosphorylation at its Ser62 residue, which has a 
stabilizing effect and is catalyzed by ERK (43).  
In total, our observations strongly suggest that both the AKT and MEK/ERK signaling 
pathways participate in orchestrating the cellular responses to NBT-272, at least in vitro. 
Moreover, combination of NBT-272 with a specific inhibitor of PI3K/mTOR, BEZ235 (39), 
seemed to further increase the NBT-272-dependent effect on cell cycle and autophagy, but not 
apoptosis. Numerous components of the AKT/mTOR and MEK/ERK pathways have been 
found deregulated in cancer, including ET. High basal activation levels of AKT and of the S6 
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ribosomal protein were documented in MB (44, 45) and a relevant role in NB pathogenesis 
was attributed to PI3K, found to be overexpressed in NB tumors (46). Phosphorylation of 
AKT, S6, and ERK has also been reported as a frequent event in NB, in which AKT 
activation in particular was correlated with diverse indicators of aggressive disease and poor 
prognosis (47). These two signaling pathways were also negatively associated with 
malignancy in childhood rhabdomyosarcoma (48) and in Ewing’s sarcoma (49), thus 
rendering it certainly worthwhile to promote the idea of developing common therapeutic 
strategies effective in different ET entities. 
Finally, NBT-272 arrested tumor growth in a xenograft model of human NB, showing that 
the potent effect of this compound could also be reproduced in vivo, with concomitant 
reduction of MYC expression and of ERK activation in the treated tumors. This very 
encouraging results warrant the extension of investigations to more ET models.  
In summary, NBT-272 induced a relatively complex pattern of cellular responses, 
including inhibition of crucial regulators of protein synthesis. All these events could be 
related functionally to interference with key cell survival pathways (AKT and MEK/ERK) 
playing a role in the pathogenesis of several ETs. Our findings increase the present level of 
understanding of the mechanisms of action of NBT-272, explaining its potent anti-tumor 
effect in in vitro as well as in vivo models of ET. This study certainly justifies further efforts 
to define more clearly the potential benefits of using NBT-272 in novel therapeutic strategies 
for pediatric tumors.  
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Figure legends 
Figure 1. Dose-dependent effect of NBT-272 on cell viability and colony formation in 
ET-derived cell lines. (A) Chemical structure of NBT-272. (B) MTS assays were performed 
72 h after addition of increasing concentrations of NBT-272 (1-182 nM) in 13 ET-derived cell 
lines. (C) The IC50 values relative to NBT-272 toxicity are listed, as calculated from the 
curves fitting the data in panel B. DAOY M2 cells (overexpressing c-MYC) are also reported. 
(D) Five cell lines were evaluated for anchorage-independent growth in soft agar. NBT-272 
reduced colony formation by 50% relative to monolayer cultures at concentrations lower 
than/similar to IC50 values. IC50 (nM): WAC-2, 2.3; SK-N-BE, 4.3; A673, 4.6; MON, < 1; 
Wit-49, 9.7. 
 
Figure 2. Induction of cell cycle arrest in MB and NB cells. (A) WAC-2, SK-N-BE, and 
SH-SY5Y cells were treated with the indicated amount of NBT-272 for 16 h, or were left 
untreated (control). The percentage of cells in different stages of the cell cycle is reported in 
each diagram. (B) WAC-2 and DAOY cells were subjected to treatment with 20 nM NBT-
272 and analyzed for expression of cell cycle-regulatory proteins by immunoblotting at 
different time points. The experiment was also confirmed in SH-SY5Y cells treated for 16 h.  
 
Figure 3. NBT-272-induced apoptosis and autophagy in ET cell lines. (A) Induction of 
apoptosis was quantified by Caspase-Glo 3/7 assay (Promega) in 10 cell lines representative 
of different ET entities, following treatment with 10/20 nM NBT-272 for 24 h. Luminescence 
signals were normalized to cell viability (MTS assay). (B) Cleavage of PARP/caspase 3 was 
evaluated by western blotting in the MB cell lines D341 and DAOY and in two NB cell lines 
(SH-SY5Y and SK-N-BE), treated as indicated. The apparent molecular weight of full length 
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and cleaved caspases-3 on the blots is indicated (35 kDa, 17-19 kDa) (C) High resolution 
electron microscopy was performed to analyze the effect of NBT-272 (20 nM, 16 h) on the 
ultrastructural organization of DAOY cells (a, c-e, h) and of SK-N-BE cells (b, f, g). Mock-
treated cells (a, b) appeared healthy with homogeneous cytoplasm and regular nuclear 
envelope. Treated cells displayed a looser cytosol and membrane blebbing at the cell surface 
(c) as well as a drastic increase in the amount of vacuoles and lysosomes (c, d). Numerous 
autophagosomes containing cellular fragments, ribosomes, and whole mitochondria could be 
detected (arrow heads). DAOY cells were treated separately with rapamycin (200 nM, 48 h) 
as control (h). Bars: a, h = 4μm, b-d, g = 2 μm, e, f = 0.5 μm. (D) Change in expression of the 
autophagy-related proteins SQSTM1 (p62) and LC-3 and of the Atg5-12 complex (markers of 
autophagosome formation) was documented by immunoblotting in DAOY cells. 
 
Figure 4. Indirect effect of NBT-272 on MYC. (A) The effect of NBT-272 on either c-MYC 
or MYCN in different ET cell lines was analyzed at the protein (western blotting) and at the 
mRNA level (qRT-PCR). (B) Cotreatment of D341 cells with MG132, inhibiting proteasome-
mediated protein degradation, rescued c-MYC from the depleting effect of NBT-272. (C) Cell 
viability was evaluated in three NB-derived cell lines (SK-N-BE, SH-SY5Y, WAC-2) 
incubated for 72 h with increasing doses of Mycro3 (33) or 10058-F4 (34). (D) Changes in 
the expression of apoptosis- (left) and cell cycle-related genes (right) were analyzed 
comparing the effect of NBT-272 (1) and of c-MYC down-regulation by siRNA (2). For the 
silencing experiment, DAOY M2 cells were transfected transiently with c-MYC siRNA and 
gene expression was analyzed after 48 h by using the RT² Profiler™ PCR Array. The same 
cell line was treated for 24 h with 20 nM NBT-272 and subjected to the same analysis. 
Results in the hit maps are expressed as the log2Ratio (Ratio=2^-ΔΔCt), obtained from NBT-
272-treated or c-MYC siRNA-transfected cells normalized to the corresponding controls (i.e. 
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mock-treated and control siRNA-transfected cells, respectively). Values in each analysis 
represent the average of three independent experiments. 
 
Figure 5. Inhibition of protein translation and of the AKT/mTOR- and ERK-dependent 
pathways. (A) Protein expression and activation status of components of the AKT/mTOR 
and ERK pathways were investigated by immunoblotting. (B) Treatment with NBT-272 
triggered a depletion of active eIF4E and 4EBP-1 proteins in different cell lines as early as 16 
h.  
 
Figure 6. Reduction of tumor growth induced by NBT-272 in a xenograft model. Female 
athymic nude mice were injected in the right flank with SH-SY5Y-LUC cells. Three weeks 
after injection, the mice were divided into two homogeneous groups (based on the amount of 
engrafted human cells). The mice received either NBT-272 (10 μM/week) or vehicle (0.003% 
EtOH/PBS), both administered three times a week. (A) The tumor growth rate was monitored 
on a weekly basis by quantifying the luciferase activity of the recombinant tumor cells in vivo 
(see scale bars) and plotted starting from the first day of treatment. Blue: vehicle-treated 
animals. Red: NBT-272-treated animals. BLI data are available as a supplementary figure 
(Fig. 7S). (B) Quantification of the tumor growth rate. (C) H&E and IHC staining of tumor 
samples obtained from mice treated either with vehicle alone (left panels) or with NBT-272 
(right panels), according to the described protocol. The panels c-d represent the enlarged view 
of the selected areas in panels a-b, respectively. In a-b the tumors are shown as hyper-dense 
rounded structures with some necrosis portions (n). In panels e-g, the tumor sections were 
stained for Ki67 (proliferation), whereas in panels i-l the staining for cleaved caspase-3 (cl-
CASP3, apoptosis) is shown. Images a-b: 5x magnification, images c-l: 40x magnification. 
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(D) Western blotting detection of c-MYC, p-ERK1/2, and p-AKT was performed in total 
protein extracts from tumors developed by mice 4 (vehicle-treated) and 9 (NBT-272-treated). 
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